Actinium Pharma up 17% premarket on encouraging Iomab-B data [Seeking Alpha]
Actinium Pharmaceuticals, Inc. (Delaware) (ATNM)
NASDAQ:AMEX Investor Relations:
ir.actiniumpharma.com
Company Research
Source: Seeking Alpha
Healthcare | On the Move Actinium Pharma up 17% premarket on encouraging Iomab-B data Feb. 21, 2020 7:57 AM ET Actinium Pharmaceutica... (ATNM) Douglas W. House Nano cap Actinium Pharmaceuticals (NYSEMKT: preliminary data SIERRA Patients undergoing bone marrow transplantation (BMT) who received Iomab-B experienced lower rates of adverse events compared to control. Specifically, the rate of febrile neutropenia was 25.8% in the Iomab-B arm compared to 42.8% in the control arm. The rates of sepsis/septic shock and stomatitis (mucositis) were 3.2% and 42.8% and 9.7% and 28.6%, respectively. Neutropenia and sepsis are typical toxicities with chemo-induced conditioning regimens. All patients receiving a therapeutic dose of Iomab-B achieved successful BMT engraftment with a 6% transplant-related mortality (TRM) rate compared to 18% successful BMT engraftment and 29% TRM rate in the control arm. The trial is ongoing with an estimated primary completion date of December. See all stocks on the
Show less
Read more
Impact Snapshot
Event Time:
ATNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATNM alerts
High impacting Actinium Pharmaceuticals, Inc. (Delaware) news events
Weekly update
A roundup of the hottest topics
ATNM
News
- Actinium Pharmaceuticals, Inc. (NYSE: ATNM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.MarketBeat
- Actinium Pharmaceuticals, Inc. (NYSE: ATNM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Related Infractions And Shareholders With Losses Are Urged To Contact The Schall Law FirmAccesswire
- Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of DirectorsPR Newswire
- The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud Accesswire
ATNM
Earnings
- 11/14/24 - Miss
ATNM
Analyst Actions
- 11/15/24 - HC Wainwright
ATNM
Sec Filings
- 11/14/24 - Form 10-Q
- 11/12/24 - Form SC
- 11/8/24 - Form SC
- ATNM's page on the SEC website